Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy: a parallel prospective cohort study in two sub-Sahara African populations
Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we investigated the impact of population and pharmacogenetic variations for efavirenz pharmacokinetics, auto-induction, and im...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 February 2020
|
| In: |
Frontiers in pharmacology
Year: 2020, Jahrgang: 11 |
| ISSN: | 1663-9812 |
| DOI: | 10.3389/fphar.2020.00026 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3389/fphar.2020.00026 Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/articles/10.3389/fphar.2020.00026/full 
|
| Verfasserangaben: | Sabina Mugusi, Abiy Habtewold, Eliford Ngaimisi, Wondwossen Amogne, Getnet Yimer, Omary Minzi, Eyasu Makonnen, Christopher Sudfeld, Jürgen Burhenne and Eleni Aklillu |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694066657 | ||
| 003 | DE-627 | ||
| 005 | 20230427100430.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200403s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2020.00026 |2 doi | |
| 035 | |a (DE-627)1694066657 | ||
| 035 | |a (DE-599)KXP1694066657 | ||
| 035 | |a (OCoLC)1341313723 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mugusi, Sabina |e VerfasserIn |0 (DE-588)1165155516 |0 (DE-627)1029320829 |0 (DE-576)510271685 |4 aut | |
| 245 | 1 | 0 | |a Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy |b a parallel prospective cohort study in two sub-Sahara African populations |c Sabina Mugusi, Abiy Habtewold, Eliford Ngaimisi, Wondwossen Amogne, Getnet Yimer, Omary Minzi, Eyasu Makonnen, Christopher Sudfeld, Jürgen Burhenne and Eleni Aklillu |
| 264 | 1 | |c 07 February 2020 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.04.2020 | ||
| 520 | |a Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we investigated the impact of population and pharmacogenetic variations for efavirenz pharmacokinetics, auto-induction, and immunologic outcome during antituberculosis treatment. A total of 921 treatment-naïve HIV patients with (196 Ethiopians and 231 Tanzanians) or without TB co-infection (285 Ethiopians and 209 Tanzanians) were enrolled and treated with efavirenz-based cART. TB-HIV patients started rifampicin-based anti-TB therapy 4 weeks before cART. Efavirenz plasma concentrations were measured on the 4th and 16th weeks of cART. Genotyping for CYP2B6, CYP3A5, ABCB1, UGT2B7, and SLCO1B1 was done. CD4 cells-count was measured at baseline, 12th, 24th and 48th weeks of cART. Among HIV-only cohort, plasma efavirenz concentration and median CD4 cell count were significantly higher in Tanzanians than Ethiopians, and both CYP2B6 genotype and population-variation were significant predictors of efavirenz plasma concentration. Within-population analyses indicated a pronounced efavirenz autoinduction in Tanzanians as reflected by a significant decrease of plasma efavirenz concentration over time (p=0.0001), but not in Ethiopians. Among TB-HIV cohort, there were no significant between-population differences in plasma efavirenz concentrations or CD4 cell-recovery, and CYP2B6 genotype but not population-variation was a significant predictor of efavirenz plasma exposure. In Tanzanian patients, short-term anti-TB co-treatment significantly reduced the mean plasma efavirenz concentration in CYP2B6*1/*1 genotype at week-4 (p=0.005), but not at week-16 of cART. In Ethiopian patients, anti-TB cotreatment increased the mean plasma efavirenz concentration among CYP2B6*6 carriers at week-4 (p=0.003) and week-16 (p=0.035) of cART. In general, long-term anti-TB co-treatment increased plasma efavirenz concentration at week 16 of cART in both Ethiopians and Tanzanians CYP2B6*6/*6 > *1/*6 > *1/*1 genotypes. In TB-HIV patients, baseline BMI, viral load, and WHO clinical-stage but not genotype, population-variation, or efavirenz concentration were significant predictors of immunologic outcome at week-48. In summary efavirenz auto-induction, pharmacokinetics, and the immunologic outcome are influenced by population-variation, anti-TB co-medication, and CYP2B6 genotype. CYP2B6 genotype is a significant predictor of efavirenz plasma exposure regardless of population-variation or antituberculosis co-treatment, but population-variation is insignificant during antituberculosis treatment. CYP2B6 genotype, population, and geographic differences need to be considered for efavirenz dosage-optimization. | ||
| 650 | 4 | |a Africa | |
| 650 | 4 | |a CYP2B6 | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Pharmacaeconomics | |
| 650 | 4 | |a Population variation | |
| 650 | 4 | |a Tuberculosis | |
| 700 | 1 | |a Habtewold, Abiy |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ngaimisi, Eliford |e VerfasserIn |4 aut | |
| 700 | 1 | |a Amogne, Wondwossen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yimer, Getnet |e VerfasserIn |4 aut | |
| 700 | 1 | |a Minzi, Omary |e VerfasserIn |4 aut | |
| 700 | 1 | |a Makonnen, Eyasu |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sudfeld, Christopher |e VerfasserIn |4 aut | |
| 700 | 1 | |a Burhenne, Jürgen |d 1963- |e VerfasserIn |0 (DE-588)1034228889 |0 (DE-627)745126987 |0 (DE-576)381858197 |4 aut | |
| 700 | 1 | |a Aklillu, Eleni |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d Lausanne : Frontiers Media, 2010 |g 11(2020) Artikel-Nummer 26, 13 Seiten |h Online-Ressource |w (DE-627)642889392 |w (DE-600)2587355-6 |w (DE-576)335527108 |x 1663-9812 |7 nnas |a Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy a parallel prospective cohort study in two sub-Sahara African populations |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |g extent:13 |a Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy a parallel prospective cohort study in two sub-Sahara African populations |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2020.00026 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fphar.2020.00026/full |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200403 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1034228889 |a Burhenne, Jürgen |m 1034228889:Burhenne, Jürgen |d 910000 |d 910100 |e 910000PB1034228889 |e 910100PB1034228889 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 999 | |a KXP-PPN1694066657 |e 3618677804 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1663-9812"],"eki":["642889392"],"zdb":["2587355-6"]},"origin":[{"publisherPlace":"Lausanne","publisher":"Frontiers Media","dateIssuedKey":"2010","dateIssuedDisp":"2010-"}],"language":["eng"],"recId":"642889392","note":["Gesehen am 08.09.20"],"disp":"Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy a parallel prospective cohort study in two sub-Sahara African populationsFrontiers in pharmacology","type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"year":"2020","text":"11(2020) Artikel-Nummer 26, 13 Seiten","volume":"11","extent":"13"},"pubHistory":["2010 -"],"title":[{"title_sort":"Frontiers in pharmacology","title":"Frontiers in pharmacology"}]}],"physDesc":[{"extent":"13 S."}],"name":{"displayForm":["Sabina Mugusi, Abiy Habtewold, Eliford Ngaimisi, Wondwossen Amogne, Getnet Yimer, Omary Minzi, Eyasu Makonnen, Christopher Sudfeld, Jürgen Burhenne and Eleni Aklillu"]},"id":{"eki":["1694066657"],"doi":["10.3389/fphar.2020.00026"]},"origin":[{"dateIssuedDisp":"07 February 2020","dateIssuedKey":"2020"}],"language":["eng"],"recId":"1694066657","type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 03.04.2020"],"person":[{"family":"Mugusi","given":"Sabina","display":"Mugusi, Sabina","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Habtewold, Abiy","given":"Abiy","family":"Habtewold"},{"role":"aut","display":"Ngaimisi, Eliford","roleDisplay":"VerfasserIn","given":"Eliford","family":"Ngaimisi"},{"family":"Amogne","given":"Wondwossen","roleDisplay":"VerfasserIn","display":"Amogne, Wondwossen","role":"aut"},{"family":"Yimer","given":"Getnet","roleDisplay":"VerfasserIn","display":"Yimer, Getnet","role":"aut"},{"family":"Minzi","given":"Omary","display":"Minzi, Omary","roleDisplay":"VerfasserIn","role":"aut"},{"given":"Eyasu","family":"Makonnen","role":"aut","roleDisplay":"VerfasserIn","display":"Makonnen, Eyasu"},{"family":"Sudfeld","given":"Christopher","roleDisplay":"VerfasserIn","display":"Sudfeld, Christopher","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Burhenne, Jürgen","given":"Jürgen","family":"Burhenne"},{"role":"aut","display":"Aklillu, Eleni","roleDisplay":"VerfasserIn","given":"Eleni","family":"Aklillu"}],"title":[{"subtitle":"a parallel prospective cohort study in two sub-Sahara African populations","title":"Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy","title_sort":"Impact of population and pharmacogenetics variations on efavirenz pharmacokinetics and immunologic outcomes during anti-tuberculosis co-therapy"}]} | ||
| SRT | |a MUGUSISABIIMPACTOFPO0720 | ||